Harshabad Singh, Rachel B Keller, Kevin S Kapner, Julien Dilly, Srivatsan Raghavan, Chen Yuan, Elizabeth F Cohen, Michael Tolstorukov, Elizabeth Andrews, Lauren K Brais, Annacarolina da Silva, Kimberly Perez, Douglas A Rubinson, Rishi Surana, Marios Giannakis, Kimmie Ng, Thomas E Clancy, Matthew B Yurgelun, Benjamin L Schlechter, Jeffrey W Clark, Geoffrey I Shapiro, Michael H Rosenthal, Jason L Hornick, Valentina Nardi, Yvonne Y Li, Hersh Gupta, Andrew D Cherniack, Matthew Meyerson, James M Cleary, Jonathan A Nowak, Brian M Wolpin, Andrew J Aguirre
PURPOSE: Approximately 8-10% of pancreatic ductal adenocarcinomas (PDAC) do not harbor mutations in KRAS. Understanding the unique molecular and clinical features of this subset of pancreatic cancer is important to guide patient stratification for clinical trials of molecularly targeted agents. EXPERIMENTAL DESIGN: We analyzed a single-institution cohort of 795 exocrine pancreatic cancer cases (including 785 PDAC cases) with a targeted multi-gene sequencing panel and identified 73 patients (9...
July 18, 2023: Clinical Cancer Research